Optic neuritis is a potentially blinding condition that frequently appears as the initial sign of demyelinating disorders like multiple sclerosis. 15% to 20% of people with multiple sclerosis experience optic neuritis as their first inflammatory event, and almost half of all multiple sclerosis patients have at least one episode of optic neuritis throughout a 15-year span. The optic neuritis pipeline analysis by Expert Market Research focuses on various treatment options for this disease.
Major companies involved in developing optic neuritis pipeline drugs include Amgen Inc., Bio-Thera Solutions and Alexion Pharmaceuticals, Inc., among others.
Leading drugs currently under the pipeline include Inebilizumab and Efgartigimod Alfa, among others.
The increasing cases of optic neuritis and the rising technological advancements are poised to positively influence the optic neuritis pipeline landscape.
The Optic Neuritis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into optic neuritis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for optic neuritis. The optic neuritis report assessment includes the analysis of over 25 pipeline drugs and 10+ companies. The optic neuritis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with optic neuritis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to optic neuritis.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Optic neuritis is an inflammatory disease that affects the optic nerve with symptoms like sudden vision loss, eye pain, and diminished color perception. It is frequently linked to autoimmune diseases like multiple sclerosis (MS). Clinical assessment, optical coherence tomography (OCT), visual acuity tests, and magnetic resonance imaging (MRI) are used in the diagnosis process to evaluate nerve damage and rule out underlying diseases. Immunosuppressive treatments such as rituximab or inebilizumab for recurring or MS-associated optic neuritis, plasma exchange for severe instances, and high-dose corticosteroids (IV methylprednisolone) to speed recovery are available as treatment options.
The field of treating optic neuritis is changing, with several interesting treatments being researched. In October 2022, the National Eye Institute was awarded with a USD 1.6 million grant to further develop TRE-515, an oral drug that targets inflammatory immune cells. Clinical trials are being conducted to see whether Oculis' OCS-05, a neuroprotective drug that inhibits Rho kinase, can help patients with optic neuritis avoid nerve damage and encourage repair. Furthermore, natalizumab (Antegren) is being investigated for its potential to prevent immune cell migration across the blood-brain barrier, which could reduce the frequency of relapses in multiple sclerosis-related optic neuritis. These advancements demonstrate the increased emphasis on cutting-edge therapies meant to enhance the prognosis of those with optic neuritis. Further, the rising focus on the development of optic neuritis emerging drugs and the advances in the understanding of the molecular pathogenesis of the disease are expected to support the pipeline expansion in the coming years.
With an estimated yearly incidence of 1 to 5 cases per 100,000 people, optic neuritis incidence and prevalence varies throughout the world. As optic neuritis is frequently a presenting sign of multiple sclerosis, the frequency may be higher in populations where the demyelinating disease is more prevalent. With a female-to-male ratio of roughly 3:1, ocular neuritis affects women more frequently than males. Young adults, usually between the ages of 20 and 50, are the most affected with optic neuritis. 32 is the typical age at which it first appears.
This section of the report covers the analysis of optic neuritis drug candidates based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials, with a substantial number of optic neuritis drugs undergoing clinical development.
The drug molecule categories covered under optic neuritis pipeline analysis include recombinant fusion proteins, small molecules, biologics, peptides, and polymers, among others. The optic neuritis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for optic neuritis.
The EMR report for the optic neuritis drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed optic neuritis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in optic neuritis clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for optic neuritis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of optic neuritis drug candidates.
The Hansoh BioMedical R&D Company created the monoclonal antibody inebilizumab, which targets CD19 to reduce B cells. In China, it is authorized for the treatment of neuromyelitis optica spectrum disorders (NMOSD), an autoimmune condition that causes inflammation of the spinal cord and optic nerve.
Argenx's neonatal Fc receptor (FcRn) blocker, efgartigimod alfa, lowers immunoglobulin G (IgG) levels by preventing their recycling. It is authorized to treat the autoimmune neuromuscular disease known as generalized myasthenia gravis. The effectiveness of efgartigimod alfa in treating acute optic neuritis, an inflammatory disorder of the optic nerve, will be assessed in pilot Phase 2 clinical research.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Optic Neuritis Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for optic neuritis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into optic neuritis collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share